REHOVOT, Israel, Aug. 15,
2023 /PRNewswire/ -- Biomica Ltd., a
clinical-stage biopharmaceutical company developing innovative
microbiome-based therapeutics and a subsidiary of Evogene
Ltd. (Nasdaq: EVGN) (TASE: EVGN), has announced the opening of
a second site at The Davidoff Cancer Center for its
ongoing Phase I clinical trial of its immuno-oncology drug
candidate, BMC128. The trial aims to assess the safety and
tolerability of BMC128 in combination with immune checkpoint
inhibitor (ICI) immunotherapy, Bristol Myers Squibb's Opdivo®, for
the treatment of refractory patients with non-small cell lung
cancer (NSCLC), melanoma, or renal cell carcinoma (RCC).
The Davidoff Center for the Treatment and Research of Cancer,
situated at Beilinson Hospital, Rabin Medical Center (RMC), holds a
preeminent position as Israel's
first and foremost comprehensive cancer center, known for its
international leadership in cancer care. This state-of-the-art and
patient-centric facility diligently serves over 200,000 patients
annually, both from Israel and
around the globe.
This new site at The Davidoff Center represents another
milestone in Biomica's commitment to advancing cutting-edge
clinical research in immuno-oncology. The company established its
first site at the Rambam Health Care Campus, where the first
patient was dosed in July 2022 in the
Phase I study of its Microbiome-Based immuno-oncology drug.
Prof. Gal Markel, Director of Davidoff Cancer Center and
Biomica's Scientific Advisory Board member, said: "I am
excited about Biomica's significant progress in their Phase I
clinical trial at The Davidoff Cancer Center. As a Biomica
Scientific Advisory Board member, I am proud to contribute my
expertise to this important research endeavor. The exploration of
microbiome-based immuno-oncology therapies represents a promising
frontier in cancer treatment. I look forward to witnessing the
potential impact of this approach on refractory patients with
NSCLC, melanoma, or RCC."
Dr. Elran Haber, CEO of Biomica, expressed his pride:
"The opening of this new site at The Davidoff Center, a
world-renowned cancer institution, marks an important milestone for
Biomica's BMC128 clinical program. Collaborating with esteemed
Prof. Gal Markel further strengthens our commitment to advancing
clinical research and expediting patient recruitment. We are
resolute in our pursuit of accelerating progress and bringing hope
to patients through innovative therapies."
About Biomica Ltd.:
Biomica is a clinical stage biopharmaceutical company developing
innovative microbiome-based therapeutics utilizing PRISM system, a
proprietary computational platform powered by Evogene's
MicroBoost AI tech-engine. licensed from Evogene. Biomica
aims to identify and characterize disease-related microbiome
entities and to develop novel therapeutics based on these
understandings. The company is focused on the development of
therapies for antibiotic resistant bacteria, immuno-oncology, and
microbiome-related gastrointestinal (GI) disorders. Biomica is a
subsidiary of Evogene Ltd. (Nasdaq: EVGN, TASE:
EVGN).
For more information, please visit www.biomicamed.com
About Evogene Ltd.:
Evogene (Nasdaq: EVGN, TASE: EVGN) is a computational biology
company aiming to revolutionize the development of
life-science-based products by utilizing cutting-edge technologies
to increase the probability of success while reducing development
time and cost. Evogene established three unique tech-engines -
MicroBoost AI, ChemPass AI, and GeneRator AI –
leveraging Big Data and Artificial Intelligence and incorporating
deep multidisciplinary understanding in life sciences. Each
tech-engine is focused on the discovery and development of products
based on one of the following core components: microbes
(MicroBoost AI), small molecules (ChemPass AI), and
genetic elements (GeneRator AI).
Evogene uses its tech-engines to develop products through
subsidiaries and strategic partnerships. Evogene's subsidiaries
currently utilize the tech-engines to develop human
microbiome-based therapeutics by Biomica, ag-biologicals by
Lavie Bio, ag-chemicals by AgPlenus,
medical cannabis products by Canonic and castor varieties, for the
biofuel and other industries, by Casterra.
For more information, please visit www.evogene.com.
Forward-Looking Statements:
This press release contains "forward-looking statements"
relating to future events. These statements may be identified by
words such as "will", "may", "could", "expects", "intends",
"anticipates", "plans", "believes", "scheduled", "estimates",
"demonstrates", or words of similar meaning. For example, Evogene
and Biomica are using forward-looking statements in this press
release when they discuss the safety and tolerability of
BMC128 and the success of microbiome-based immuno-oncology
therapies in cancer treatment. Such statements are based on
current expectations, estimates, projections and assumptions,
describe opinions about future events, and involve certain risks
and uncertainties which are difficult to predict and are not
guarantees of future performance. Therefore, actual future results,
performance or achievements of Evogene and its subsidiaries may
differ materially from what is expressed or implied by such
forward-looking statements due to a variety of factors, many of
which are beyond the control of Evogene and its subsidiaries,
including, without limitation, those risk factors contained in
Evogene's reports filed with applicable securities authorities.
Evogene and its subsidiaries disclaim any obligation or commitment
to update these forward-looking statements to reflect future events
or developments or changes in expectations, estimates, projections,
and assumptions.
Contacts
Rachel Pomerantz Gerber
Head of Investor Relations at Evogene
rachel.pomerantz@evogene.com
Tel: +972-8-9311901
Logo - https://mma.prnewswire.com/media/1974949/Biomica.jpg
Logo - https://mma.prnewswire.com/media/1947468/Evogene.jpg
View original
content:https://www.prnewswire.com/news-releases/biomica-opens-second-site-to-advance-its-immuno-oncology-drug-trials-at-davidoff-center-301900788.html
SOURCE Biomica Ltd.